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Volume 51, Number 4 Abstracts 1067Objectives: A systematic review was performed to summarise out-
comes of acute thrombosed popliteal artery aneurysms (PAAs) treated with
thrombolysis or thrombectomy followed by bypass.
Methods: A systematic review was conducted of data on acute throm-
bosed PAAs dated 1 January 1990 through 30 June 2008 using the
Cochrane Library, MEDLINE and EMBASE databases. Primary endpoint
was limb salvage; secondary endpoints were mortality and patency of the
bypasses.
Results: Eight prospective studies and 25 retrospective studies with
895 patients presenting with acute ischaemia were included. No randomised
trials were included. The mortality rate after surgical repair was 3.2% (95%
confidence interval (C.I.) 1.8–4.6). The amputation rate was 14.1% (95%
C.I. 11.8–16.4). Thrombolysis before surgery did not result in a significant
reduction of the number of amputations, compared with surgery (throm-
bectomy and bypass) alone. The mean primary patency rates of the bypasses
at 1, 3 and 5 years were 79%, 77% and 74%, respectively, in the ‘thrombol-
ysis’ group and 71% (P  0.026), 54% (P  0.164) and 45% (P  0.249) in
the ‘thrombectomy’ group. No distinction could be made regarding sec-
ondary patency and limb-salvage rates between the groups owing to insuf-
ficient data.
Conclusions: Preoperative and intra-operative thrombolyses result in a
significant improvement in 1-year primary graft patency rates, but do not result
in a significant reduction for amputations compared with surgery alone.
Review of Direct Anatomical Open Surgical Management of Athero-
sclerotic Aorto-Iliac Occlusive Disease
Chiu K.W.H., Davies R.S.M., Nightingale P.G., Bradbury A.W., AdamD.J.
Eur J Vasc Endovasc Surg 2010;39:460-71.
Background: Aortofemoral bypass(AFB), iliofemoral bypass(IFB),
and aortoiliac endarterectomy(AIE) are the three most common techniques
for anatomical open surgical revascularisation for patients with aorto-iliac
occlusive disease(AIOD), but the optimal method of reconstruction is
unknown.
Aims: To review and compare mortality, morbidity and short- and
long-term patency rates for AFB, IFB and AIE in patients with AIOD
reported in the English language literature.
Methods: A MEDLINE(1970–2007) and Cochrane Library search
for articles relating to AFB, IFB, AIE and AIOD was undertaken. Studies
were included if: a) patency rates based on life-tables were available, and b)
patient/study characteristics were reported.
Results: 29 studies(5738 patients) for AFB, 11 studies(778 patients)
for IFB and 11 studies(1490 patients) for AIE were included. Operative
mortality was 4.1% for AFB, 2.7% for IFB and 2.7% for AIE (p  0.0001).
Systemic morbidity was 16.0% for AFB, 18.9% for IFB and 12.5% for AIE
(p  0.05). Overall 5-year primary patency rates were 86.2%, 85.3% and
88.2% for AFB, IFB and AIE, respectively (p  NS).
Conclusion: Aorto-iliac endarterectomy was associated with signifi-
cantly lower peri-operative morbidity and mortality rates compared withReaders can access EJVES articles at http://intl.eImmunomodulation of Vascular Diseases: Atherosclerosis and
Autoimmunity
Shi G-P. Eur J Vasc Endovasc Surg 2010;39:485-94.
The autoimmune disease atherosclerosis contributes to several vascular
complications. Besides vascular cells, inflammatory cells occur prominently
in atherosclerotic lesions; lymphocytes play a detrimental role in the initia-
tion and progression of this common vascular disease. Recent discoveries
have led to the identification of several important lymphocyte types within
the atherosclerotic lesions. However, peripheral lymphocytes and those in
the lymphoid organs both figure critically in the regulation of atherosclerotic
lesion growth. Although the concept of atherosclerosis as an autoimmune
disease is well known, the ways in which autoantigens and autoantibodies
contribute to atherogenesis in human or even in animal models remains
largely unknown. For example, autoantigen immunisation can either pro-
mote or attenuate atherogenesis in animals, depending on the antigen types
and the routes and carriers of immunisation. This article summarises recent
findings regarding lesion inflammatory cell types, autoantigens and autoan-
tibody isotypes that can affect the initiation and progression of atheroscle-
rosis from both human and animal studies.
Randomised Clinical Trial of Foam Sclerotherapy for Patients with a
Venous Leg Ulcer
O’Hare J.L., Earnshaw J.J. Eur J Vasc Endovasc Surg 2010;39:495-9.
Objectives: To assess whether routine use of foam sclerotherapy, in
addition to four-layer compression bandaging, could speed up the healing of
venous ulcers.
Design: Randomised controlled trial involving patients recruited from
a nurse-led leg ulcer clinic. A total of 315 new patients were assessed, and
eleven patients were identified from follow-up clinics.
Methods: Inclusion criteria were: patients with an active venous leg
ulcer, in the presence of superficial truncal venous incompetence and with-
out total deep venous incompetence on duplex imaging. Patients were
randomised to four-layer compression bandages alone (control) or with
additional foam sclerotherapy to incompetent superficial truncal veins. The
primary endpoint was ulcer healing 24 weeks after randomisation.
Results: It was only possible to recruit 40 patients who were suitable
for analysis: 22 control, 18 additional foam sclerotherapy. There was no
complication from the foam treatment and at six months the target vein was
occluded in 9 of 11 evaluable patients that had foam. One patient died
before 24 weeks from an unrelated cause. At 24 weeks, 17 of 20 (85% - 1
died) in the control group and 12 of 13 (92%) patients with additional foam
sclerotherapy had ulcer healing (P0.72, log rank testing).
Conclusion: This trial failed to recruit sufficient patients for formal
comparison, but foam sclerotherapy was feasible as an adjunct to compres-bypass grafting. All three techniques were equally effective in terms of
long-term patency.
sion therapy for venous ulceration. Trial registration: Eudra CT 2005-
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